Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 13/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 13/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 10/20 | 1.00 |
| ▸ | CDK2 | P24941 | 10/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 10/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 9/20 | 1.00 |
| ▸ | CDK1 | P06493 | 8/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Purvalanola SCHEMBL30375366 | 1.00 | CDK5 (1.00) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| Purvalanola SCHEMBL1217069 | 1.00 | CDK5 (1.00) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| Purvalanola SCHEMBL3311119 | 1.00 | CDK5 (1.00) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| Aminopurvalanol SCHEMBL2170683 | 0.87 | CDK1 (1.00) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| Aminopurvalanol SCHEMBL29386084 | 0.87 | CDK1 (1.00) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| Aminopurvalanol SCHEMBL23752328 | 0.87 | CDK1 (1.00) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| Aminopurvalanol SCHEMBL21168739 | 0.87 | CDK1 (1.00) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL13638193 | 0.86 | CDK5 (0.76) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL7526656 | 0.85 | CDK1 (0.82) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL20694113 | 0.85 | CDK5 (0.77) | CDK5CDK5R1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 425 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698175-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-02-25 | — | — | EP | claimed |
| US-20250332145-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2025-10-30 | — | — | US | claimed |
| US-12383529-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2025-08-12 | — | — | US | claimed |
| EP-4529926-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | Ascentawits Pharmaceuticals, Ltd. (CN) | 2025-04-02 | — | — | EP | claimed |
| US-20250084089-A1 | Unique and Selective Targeting of CDK Activity in Aggressive Carcinomas | UNIVERSITY OF WINDSOR (CA) | 2025-03-13 | — | — | US | claimed |
| US-12187698-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2025-01-07 | — | — | US | claimed |
| CN-119233822-A | Methods of treating cancer using alkylating agent prodrugs and cell cycle inhibitors in combination | 深圳艾欣达伟医药科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| EP-4480494-A1 | COMPOSITION FOR USE IN TREATMENT OF CANCER, INFLAMMATORY DISEASES, OR OBESITY, AND USE THEREOF | National University Corporation Tokyo Medical and Dental University (JP) | 2024-12-25 | — | — | EP | claimed |
| US-20240390325-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2024-11-28 | — | — | US | claimed |
| WO-2024217502-A1 | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITOR COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-10-24 | — | — | WO | claimed |
| US-20220403469-A1 | Precision Medicine for Schizophrenia and Psychotic Disorders: Objective Assessment, Risk Prediction, Pharmacogenomics, and Repurposed Drugs | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-12-22 | — | — | US | claimed |
| EP-4091610-A1 | INHIBITORS OF DREAM COMPLEX ASSEMBLY AND/OR FUNCTION FOR USE IN REPAIRING DNA DAMAGE | Schumacher, Björn (DE) | 2022-11-23 | — | — | EP | claimed |
| EP-4091611-A1 | INHIBITORS OF DREAM COMPLEX ASSEMBLY AND/OR FUNCTION FOR USE IN REPAIRING DNA DAMAGE | Schumacher, Björn (DE) | 2022-11-23 | — | — | EP | claimed |
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-13 | — | — | US | claimed |
| US-11452716-B2 | Pharmaceutical composition and use thereof | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-09-27 | — | — | US | claimed |
| US-20220211860-A1 | PEPTIDE DERIVATIVES AND CONJUGATES THEREOF FOR TREATING CANCER | THE UNIVERSITY OF SYDNEY (AU) | 2022-07-07 | — | — | US | claimed |
| US-20220202950-A1 | COMPOSITIONS COMPRISING BACTERIALLY DERIVED INTACT MINICELLS FOR THERANOSTIC APPLICATIONS | ENGENEIC MOLECULAR DELIVERY PTY LTD (AU) | 2022-06-30 | — | — | US | claimed |
| US-20220168273-A1 | Pharmaceutical Combination for the Treatment of Cancer | Piramal Enterprises Limited (IN) | 2022-06-02 | — | — | US | claimed |
| EP-3962927-A1 | PEPTIDE DERIVATIVES AND CONJUGATES THEREOF FOR TREATING CANCER | The University of Sydney (AU) | 2022-03-09 | — | — | EP | claimed |
| US-11234963-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2022-02-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084089-A1 | Unique and Selective Targeting of CDK Activity in Aggressive Carcinomas | CDK4, CDK3, CDKN1A | CDK5 15/4885CDK5R1 32/4885CCNA2 18/4885 |
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | CDK5 2068/4885CDK5R1 1638/4885CCNA2 170/4885 |
| US-11452716-B2 | Pharmaceutical composition and use thereof | TP53, RB1, CDK20 | CDK5 17/4885CDK5R1 67/4885CCNA2 53/4885 |
| US-12187698-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | CDK5 2068/4885CDK5R1 1638/4885CCNA2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.